INDUSTRY OVERVIEW

Competitive Landscape

As of May 10, 2018, there are five marketed PD-1 and PD-L1 antibodies globally,
including PD-1 antibodies Keytruda and Opdivo and PD-L1 antibodies Tecentriq, Bavencio
and Imfinzi.

PD-1 Antibodies

From 2014 to 2017, the global sales revenue of Opdivo increased from US$20 million to
US$5,753 million, and the global sales revenue of Keytruda increased from US$55 million to
US$3,809 million, due to the increasing number of approved indications and higher adoption
by physicians. The diagram below summarizes the approved indications of Keytruda and
Opdivo, as well as the global sales revenue of Keytruda and Opdivo from 2014 to 2017.

Drugs

Indications

Approval
(MM/YY)

Unresectable or metastatic Melanoma
Squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Renal Cell Carcinoma

Classical Hodgkin Lymphoma

Head and Neck Squamous Cell Cancer

Urothelial Carcinoma

MSI-H or dMMR Metastatic 

Colorectal Cancer

Hepatocellular Carcinoma

Adjuvant Treatment for Melanoma
BRAF V600 Wild-Type Melanoma

Unresectable or Metastatic Melanoma

First-line Renal Cell Carcinoma

Unresectable or Metastatic Melanoma

Non-small Cell Lung Cancer

First-line Melanoma

Head and neck squamous cell cancer

First-line NSCLC

Classical Hodgkin Lymphoma

Urothelial carcinoma

Microsatellite Instability-High Cancer

Opdivo®

(nivolumab)

in combination
with ipilimumab

Keytruda®

(pembrolizumab)

Gastric or Gastroesophageal Junction Cancer

Recurrent or Metastatic Cervical Cancer

Primary Mediastinal Large

B-Cell Lymphoma

Dec-14
Mar-15
Oct-15
Nov-15
May-16
Nov-16
Feb-17
Aug-17

Sep-17
Dec-17
Oct-15
Jan-16
Apr-18
Sep-14
Oct-15
Dec-15
Aug-16
Oct-16
Mar-17
May-17
May-17
Sep-17
Jun-18
Jun-18

in combination
with pemetrexed
and carboplatin

Metastatic Nonsquamous NSCLC

May-17

Source: FDA; Frost & Sullivan

Global Sales Revenue of Opdivo,

2014-2017

5,753

Million USD

4,676

997

20

2014

2015

2016

2017

Global Sales Revenue of Keytruda,

2014-2017

3,809

Million USD

1,402

566

55

2014

2015

2016

2017

– 154 –

